So should Sutro Biopharma (NASDAQ:STRO) shareholders be worried about its cash burn? In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a ...
TimesMachine is an exclusive benefit for home delivery and digital subscribers. Full text is unavailable for this digitized archive article. Subscribers may view the full text of this article in ...
In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Sutro Biopharma (STRO – Research Report), with a price target of $17.00. Discover outperforming stocks ...
Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Sutro Biopharma (STRO – Research Report) today and set a price target of $11.00. The company’s shares closed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback